GRN-300 to boost ovarian cancer treatments and T-cell cancer killing
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
GRN-300 is being combined with chemotherapy and PARP blocker drugs to help treatments work better and strengthen the immune system in people with ovarian cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11159403 on NIH RePORTER |
What this research studies
This program is completing early human testing of GRN-300, a drug that blocks SIK2 and may make chemotherapy and PARP blockers more effective. Early parts of the trial will find safe dose levels and then expand to see how patients respond, while measuring drug levels and biological effects in the tumor. Lab work shows GRN-300 can lower DNA repair activity in cancer cells and improve how T cells kill tumor cells, which could help even cancers that don't have the usual DNA-repair defects. If you join, you would have regular clinic visits for treatment, scans, and blood or tumor samples so doctors can track safety and signs the drug is working.
Who could benefit from this research
Good fit: Adults with advanced or recurrent ovarian cancer who meet early-phase clinical trial eligibility and can attend the MD Anderson trial site would be typical candidates.
Not a fit: People without ovarian cancer, those who are medically unfit for an early-phase trial, or those who cannot travel to the trial site are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, GRN-300 could make existing ovarian cancer therapies work better, delay or overcome drug resistance, and boost anti-tumor immune responses.
How similar studies have performed: Preclinical studies show promising synergy with PARP inhibitors and a first-in-human trial was already started in an earlier SPORE cycle, but clear clinical benefit has not yet been proven.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Bast, Robert C — University of Tx Md Anderson Can Ctr
- Study coordinator: Bast, Robert C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.